Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study
Information about histiocytic disease in cats is limited. The aim of this study was to document clinical findings and outcome in feline histiocytic disorders, and characterize the expression of PDGFRβ and KIT in order to identify potential treatment targets. Morphologically diagnosed feline histiocy...
Gespeichert in:
| Veröffentlicht in: | Veterinary & comparative oncology 2017-03, Vol.15 (1), p.65-77 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 1 |
| container_start_page | 65 |
| container_title | Veterinary & comparative oncology |
| container_volume | 15 |
| creator | Treggiari, E. Ressel, L. Polton, G. A. Benoit, J. Desmas, I. Blackwood, L. |
| description | Information about histiocytic disease in cats is limited. The aim of this study was to document clinical findings and outcome in feline histiocytic disorders, and characterize the expression of PDGFRβ and KIT in order to identify potential treatment targets. Morphologically diagnosed feline histiocytic tumours were reviewed and characterized by immunohistochemistry (IHC). Five cases of feline progressive histiocytosis (FPH), eight histiocytic sarcomas (HS) and two haemophagocytic histiocytic sarcomas (HaeHS) were confirmed. PDGFRβ was variably positive in most histiocytic cases, while KIT was negative in all. Clinical presentation, treatment and outcome were also evaluated. Partial responses were recorded in measurable disease with tyrosine kinase inhibitors and lomustine, and radiotherapy achieved long‐term control in some cases. Survival times were shortest in HaeHS and disseminated disease. PDGFRβ, but not KIT, may represent a therapeutic target in feline histiocytic disorders but more studies are needed to investigate other potential treatment targets. |
| doi_str_mv | 10.1111/vco.12142 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826612497</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826612497</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3252-839c362bbc98488e8db8fac591004f8c11bed9e0267a8f723dfcd4c6ec74d14d3</originalsourceid><addsrcrecordid>eNp1kEFOwzAQAC0EoqVw4APIR5BIGztO4nBDgZaKSkWocI0ceyOMkrjYCZBv8RDeRKCFG76stZqdwyB0TPwx6d_kVZoxoYTRHTQkLI68kNNk9-9P_AE6cO7Z9yllAd1HAxpGUUiCeIhEWupaS1Fi0zbSVHCO765m0_vPDyxqhW_nKwzvawvOaVNjXeMC-gPAT9o12siu0RIr7YxVYN0FFrhqy34HdWMBu6ZV3SHaK0Tp4Gg7R-hher1Kb7zFcjZPLxeeDGhIPR4kMohonsuEM86Bq5wXQoYJ8X1WcElIDioBn0ax4EVMA1VIxWQEMmaKMBWM0OnGu7bmpQXXZJV2EspS1GBalxFOo4hQlsQ9erZBpTXOWSiytdWVsF1G_Oy7aNYXzX6K9uzJVtvmFag_8jdhD0w2wJsuofvflD2my43yC83bgQs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826612497</pqid></control><display><type>article</type><title>Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Treggiari, E. ; Ressel, L. ; Polton, G. A. ; Benoit, J. ; Desmas, I. ; Blackwood, L.</creator><creatorcontrib>Treggiari, E. ; Ressel, L. ; Polton, G. A. ; Benoit, J. ; Desmas, I. ; Blackwood, L.</creatorcontrib><description>Information about histiocytic disease in cats is limited. The aim of this study was to document clinical findings and outcome in feline histiocytic disorders, and characterize the expression of PDGFRβ and KIT in order to identify potential treatment targets. Morphologically diagnosed feline histiocytic tumours were reviewed and characterized by immunohistochemistry (IHC). Five cases of feline progressive histiocytosis (FPH), eight histiocytic sarcomas (HS) and two haemophagocytic histiocytic sarcomas (HaeHS) were confirmed. PDGFRβ was variably positive in most histiocytic cases, while KIT was negative in all. Clinical presentation, treatment and outcome were also evaluated. Partial responses were recorded in measurable disease with tyrosine kinase inhibitors and lomustine, and radiotherapy achieved long‐term control in some cases. Survival times were shortest in HaeHS and disseminated disease. PDGFRβ, but not KIT, may represent a therapeutic target in feline histiocytic disorders but more studies are needed to investigate other potential treatment targets.</description><identifier>ISSN: 1476-5810</identifier><identifier>EISSN: 1476-5829</identifier><identifier>DOI: 10.1111/vco.12142</identifier><identifier>PMID: 25665137</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Biomarkers, Tumor ; Cat Diseases - diagnosis ; Cat Diseases - metabolism ; Cat Diseases - pathology ; Cats ; chemotherapy ; Databases as Topic ; Female ; histiocytic ; Histiocytic Disorders, Malignant - metabolism ; Histiocytic Disorders, Malignant - pathology ; Histiocytic Disorders, Malignant - therapy ; Histiocytic Disorders, Malignant - veterinary ; Immunohistochemistry - veterinary ; Male ; Neoplasm Staging ; PDGFR ; Proto-Oncogene Proteins c-kit - biosynthesis ; Radiotherapy ; Receptor, Platelet-Derived Growth Factor beta - biosynthesis ; Treatment Outcome ; United Kingdom</subject><ispartof>Veterinary & comparative oncology, 2017-03, Vol.15 (1), p.65-77</ispartof><rights>2015 John Wiley & Sons Ltd</rights><rights>2015 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3252-839c362bbc98488e8db8fac591004f8c11bed9e0267a8f723dfcd4c6ec74d14d3</citedby><cites>FETCH-LOGICAL-c3252-839c362bbc98488e8db8fac591004f8c11bed9e0267a8f723dfcd4c6ec74d14d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fvco.12142$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fvco.12142$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25665137$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Treggiari, E.</creatorcontrib><creatorcontrib>Ressel, L.</creatorcontrib><creatorcontrib>Polton, G. A.</creatorcontrib><creatorcontrib>Benoit, J.</creatorcontrib><creatorcontrib>Desmas, I.</creatorcontrib><creatorcontrib>Blackwood, L.</creatorcontrib><title>Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study</title><title>Veterinary & comparative oncology</title><addtitle>Vet Comp Oncol</addtitle><description>Information about histiocytic disease in cats is limited. The aim of this study was to document clinical findings and outcome in feline histiocytic disorders, and characterize the expression of PDGFRβ and KIT in order to identify potential treatment targets. Morphologically diagnosed feline histiocytic tumours were reviewed and characterized by immunohistochemistry (IHC). Five cases of feline progressive histiocytosis (FPH), eight histiocytic sarcomas (HS) and two haemophagocytic histiocytic sarcomas (HaeHS) were confirmed. PDGFRβ was variably positive in most histiocytic cases, while KIT was negative in all. Clinical presentation, treatment and outcome were also evaluated. Partial responses were recorded in measurable disease with tyrosine kinase inhibitors and lomustine, and radiotherapy achieved long‐term control in some cases. Survival times were shortest in HaeHS and disseminated disease. PDGFRβ, but not KIT, may represent a therapeutic target in feline histiocytic disorders but more studies are needed to investigate other potential treatment targets.</description><subject>Animals</subject><subject>Biomarkers, Tumor</subject><subject>Cat Diseases - diagnosis</subject><subject>Cat Diseases - metabolism</subject><subject>Cat Diseases - pathology</subject><subject>Cats</subject><subject>chemotherapy</subject><subject>Databases as Topic</subject><subject>Female</subject><subject>histiocytic</subject><subject>Histiocytic Disorders, Malignant - metabolism</subject><subject>Histiocytic Disorders, Malignant - pathology</subject><subject>Histiocytic Disorders, Malignant - therapy</subject><subject>Histiocytic Disorders, Malignant - veterinary</subject><subject>Immunohistochemistry - veterinary</subject><subject>Male</subject><subject>Neoplasm Staging</subject><subject>PDGFR</subject><subject>Proto-Oncogene Proteins c-kit - biosynthesis</subject><subject>Radiotherapy</subject><subject>Receptor, Platelet-Derived Growth Factor beta - biosynthesis</subject><subject>Treatment Outcome</subject><subject>United Kingdom</subject><issn>1476-5810</issn><issn>1476-5829</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEFOwzAQAC0EoqVw4APIR5BIGztO4nBDgZaKSkWocI0ceyOMkrjYCZBv8RDeRKCFG76stZqdwyB0TPwx6d_kVZoxoYTRHTQkLI68kNNk9-9P_AE6cO7Z9yllAd1HAxpGUUiCeIhEWupaS1Fi0zbSVHCO765m0_vPDyxqhW_nKwzvawvOaVNjXeMC-gPAT9o12siu0RIr7YxVYN0FFrhqy34HdWMBu6ZV3SHaK0Tp4Gg7R-hher1Kb7zFcjZPLxeeDGhIPR4kMohonsuEM86Bq5wXQoYJ8X1WcElIDioBn0ax4EVMA1VIxWQEMmaKMBWM0OnGu7bmpQXXZJV2EspS1GBalxFOo4hQlsQ9erZBpTXOWSiytdWVsF1G_Oy7aNYXzX6K9uzJVtvmFag_8jdhD0w2wJsuofvflD2my43yC83bgQs</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Treggiari, E.</creator><creator>Ressel, L.</creator><creator>Polton, G. A.</creator><creator>Benoit, J.</creator><creator>Desmas, I.</creator><creator>Blackwood, L.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201703</creationdate><title>Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study</title><author>Treggiari, E. ; Ressel, L. ; Polton, G. A. ; Benoit, J. ; Desmas, I. ; Blackwood, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3252-839c362bbc98488e8db8fac591004f8c11bed9e0267a8f723dfcd4c6ec74d14d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Biomarkers, Tumor</topic><topic>Cat Diseases - diagnosis</topic><topic>Cat Diseases - metabolism</topic><topic>Cat Diseases - pathology</topic><topic>Cats</topic><topic>chemotherapy</topic><topic>Databases as Topic</topic><topic>Female</topic><topic>histiocytic</topic><topic>Histiocytic Disorders, Malignant - metabolism</topic><topic>Histiocytic Disorders, Malignant - pathology</topic><topic>Histiocytic Disorders, Malignant - therapy</topic><topic>Histiocytic Disorders, Malignant - veterinary</topic><topic>Immunohistochemistry - veterinary</topic><topic>Male</topic><topic>Neoplasm Staging</topic><topic>PDGFR</topic><topic>Proto-Oncogene Proteins c-kit - biosynthesis</topic><topic>Radiotherapy</topic><topic>Receptor, Platelet-Derived Growth Factor beta - biosynthesis</topic><topic>Treatment Outcome</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Treggiari, E.</creatorcontrib><creatorcontrib>Ressel, L.</creatorcontrib><creatorcontrib>Polton, G. A.</creatorcontrib><creatorcontrib>Benoit, J.</creatorcontrib><creatorcontrib>Desmas, I.</creatorcontrib><creatorcontrib>Blackwood, L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Veterinary & comparative oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Treggiari, E.</au><au>Ressel, L.</au><au>Polton, G. A.</au><au>Benoit, J.</au><au>Desmas, I.</au><au>Blackwood, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study</atitle><jtitle>Veterinary & comparative oncology</jtitle><addtitle>Vet Comp Oncol</addtitle><date>2017-03</date><risdate>2017</risdate><volume>15</volume><issue>1</issue><spage>65</spage><epage>77</epage><pages>65-77</pages><issn>1476-5810</issn><eissn>1476-5829</eissn><abstract>Information about histiocytic disease in cats is limited. The aim of this study was to document clinical findings and outcome in feline histiocytic disorders, and characterize the expression of PDGFRβ and KIT in order to identify potential treatment targets. Morphologically diagnosed feline histiocytic tumours were reviewed and characterized by immunohistochemistry (IHC). Five cases of feline progressive histiocytosis (FPH), eight histiocytic sarcomas (HS) and two haemophagocytic histiocytic sarcomas (HaeHS) were confirmed. PDGFRβ was variably positive in most histiocytic cases, while KIT was negative in all. Clinical presentation, treatment and outcome were also evaluated. Partial responses were recorded in measurable disease with tyrosine kinase inhibitors and lomustine, and radiotherapy achieved long‐term control in some cases. Survival times were shortest in HaeHS and disseminated disease. PDGFRβ, but not KIT, may represent a therapeutic target in feline histiocytic disorders but more studies are needed to investigate other potential treatment targets.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>25665137</pmid><doi>10.1111/vco.12142</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1476-5810 |
| ispartof | Veterinary & comparative oncology, 2017-03, Vol.15 (1), p.65-77 |
| issn | 1476-5810 1476-5829 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826612497 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Biomarkers, Tumor Cat Diseases - diagnosis Cat Diseases - metabolism Cat Diseases - pathology Cats chemotherapy Databases as Topic Female histiocytic Histiocytic Disorders, Malignant - metabolism Histiocytic Disorders, Malignant - pathology Histiocytic Disorders, Malignant - therapy Histiocytic Disorders, Malignant - veterinary Immunohistochemistry - veterinary Male Neoplasm Staging PDGFR Proto-Oncogene Proteins c-kit - biosynthesis Radiotherapy Receptor, Platelet-Derived Growth Factor beta - biosynthesis Treatment Outcome United Kingdom |
| title | Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T00%3A54%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcome,%20PDGFR%CE%B2%20and%20KIT%20expression%20in%20feline%20histiocytic%20disorders:%20a%20multicentre%20study&rft.jtitle=Veterinary%20&%20comparative%20oncology&rft.au=Treggiari,%20E.&rft.date=2017-03&rft.volume=15&rft.issue=1&rft.spage=65&rft.epage=77&rft.pages=65-77&rft.issn=1476-5810&rft.eissn=1476-5829&rft_id=info:doi/10.1111/vco.12142&rft_dat=%3Cproquest_cross%3E1826612497%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826612497&rft_id=info:pmid/25665137&rfr_iscdi=true |